Effect of Peroxisome Proliferator—Activated Receptor Gamma Agonists on Myofibroblast Differentiation and Collagen Production in Nasal Polyp—Derived Fibroblasts
Restricted accessResearch articleFirst published online October, 2009
Effect of Peroxisome Proliferator—Activated Receptor Gamma Agonists on Myofibroblast Differentiation and Collagen Production in Nasal Polyp—Derived Fibroblasts
We investigated the effect of transforming growth factor-β1 (TGF-β1) on the differentiation of nasal polyp–derived fibroblasts (NPDFs) and on their production of collagen, and investigated the effect of peroxisome proliferator-activated receptor γ (PPARγ) agonists on the effects of TGF-β1.
Methods:
Primary fibroblast lines were established from 5 human nasal polyp tissues. We activated the NPDFs with TGF-β1 and exposed them to the PPARγ agonists ciglitazone and 15-deoxy-A-prostaglandin J2. The expression of α-smooth muscle actin (α-SMA) and collagen was measured by reverse transcriptase–polymerase chain reactions, immunocytochemical staining, and collagen assays.
Results:
The treatment with TGF-β1 increased the expression of α-SMA and collagen, and expression was markedly attenuated by the PPARγ agonists.
Conclusions:
PPARγ agonists inhibit the differentiation of TGF-β1–activated NPDFs and their production of collagen.
PawliczakRLewandowska-PolakAKowalskiML. Pathogenesis of nasal polyps: An update. Curr Allergy Asthma Rep2005;5:463–71.
2.
WangQPEscudierERoudot-ThoravalFSamadI Abd-AlPeynegreRCosteA. Myofibroblast accumulation induced by transforming growth factor–beta is involved in the pathogenesis of nasal polyps. Laryngoscope1997;107:926–31.
3.
Levi-SchafferFGarbuzenkoERubinA. Human eosinophils regulate human lung- and skin-derived fibroblast properties in vitro: A role for transforming growth factor beta (TGF-beta). Proc Natl Acad Sci U S A1999;96:9660–5.
4.
BradleyDTKountakisSE. Role of interleukins and transforming growth factor–beta in chronic rhinosinusitis and nasal polyposis. Laryngoscope2005;115:684–6.
5.
LuXLiuZCuiY. The protein expression difference of transforming growth factor betal, matrix metalloproteinases 1,7,9 and tissue inhibitors of matrix metalloproteinases–1 between chronic rhinosinusitis, nasal polyps and normal mucosa tissues [in Chinese]. Lin Chuang Er Bi Yan Hou Ke Za Zhi2005;19:633–5.
6.
LittleSCEarlySBWoodardCR. Dual action of TGF-betal on nasal-polyp derived fibroblasts. Laryngoscope2008;118:320–4.
7.
BardotOAldridgeTCLatruffeNGreenS. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun1993;192:37–45.
8.
ZiouzenkovaOPlutzkyJ. Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR-RXR complex. FEBS Lett2008;582:32–8.
9.
LenhardJM. PPAR gamma/RXR as a molecular target for diabetes. Receptors Channels2001;7:249–58.
10.
KnappPJarzabekKBlachnioAZbrochT. The role of peroxisome proliferator–activated receptors (PPAR) in carcinogenesis [in Polish]. Ginekol Pol2006;77:643–51.
11.
TakanoHHasegawaHZouYKomuroI. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des2004;10:2779–86.
12.
KangHJCinnYGHwangSJ. Up-regulation of peroxisome proliferator–activated receptor gamma in perennial allergic rhinitis. Arch Otolaryngol Head Neck Surg2006;132:1196–200.
13.
CardellLOHäggeMUddmanRAdnerM. Downregulation of peroxisome proliferator–activated receptors (PPARs) in nasal polyposis. Respir Res2005;6:132.
14.
LakatosHFThatcherTHKottmannRMGarciaTMPhippsRPSimePJ. The role of PPARs in lung fibrosis. PPAR Res2007;2007:71323.
15.
FrancisGAAnnicotteJSAuwerxJ. PPAR-alpha effects on the heart and other vascular tissues. Am J Physiol Heart Circ Physiol2003;285:H1–H9.
16.
WangWLiuFChenN. Peroxisome proliferator–activated receptor — Gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-betal in renal interstitial fibroblasts. Mediators Inflamm2007;2007:62641.
17.
BelvisiMGHeleDJBirrellMA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol2006;533:101–9.
GuLZhuYJGuoZJXuXXXuWB. Effect of IFN-gamma and dexamethasone on TGF-beta1–induced human fetal lung fibroblast-myofibroblast differentiation. Acta Pharmacol Sin2004;25:1479–88.
20.
BalakumarPRoseMSinghM. PPAR ligands: Are they potential agents for cardiovascular disorders?. Pharmacology2007;80:1–10.
21.
BeckerJDelayre-OrthezCFrossardNPonsF. Regulation of inflammation by PPARs: A future approach to treat lung inflammatory diseases?. Fundam Clin Pharmacol2006;20:429–47.
22.
PicardFAuwerxJ. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr2002;22:167–97.
23.
YuanGJZhangMLGongZJ. Effects of PPARg agonist pioglitazone on rat hepatic fibrosis. World J Gastroenterol2004;10:1047–51.
24.
IglarzMTouyzRMVielEC. Peroxisome proliferator–activated receptor–alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension2003;42:737–43.
25.
CalkinACGiuntiSJandeleit-DahmKAAllenTJCooperMEThomasMC. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant2006;21:2399–405.
26.
HondaKMarquilliesPCapronMDombrowiczD. Peroxisome proliferator–activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J Allergy Clin Immunol2004;113:882–8.
27.
SimePJ. The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis. J Investig Med2008;56:534–8.
